GG8單克隆抗體與人VISTA（含V型免疫球蛋白結(jié)構(gòu)域的T細(xì)胞活化抑制劑）反應(yīng)，VISTA是B7家族的陰性檢查點(diǎn)調(diào)節(jié)因子（NCR）。幾項(xiàng)體外和體內(nèi)研究表明，VISTA蛋白既是配體又是受體。VISTA主要由髓系細(xì)胞和T細(xì)胞表達(dá)，在中樞神經(jīng)系統(tǒng)中，VISTA也由小膠質(zhì)細(xì)胞和內(nèi)皮細(xì)胞表達(dá)。與其他NCR蛋白不同，VISTA在幼稚T細(xì)胞上表達(dá)，其表達(dá)受T細(xì)胞活化的負(fù)調(diào)控。除了在調(diào)節(jié)T細(xì)胞靜止（即抑制T細(xì)胞）中的作用外，VISTA還參與髓系細(xì)胞的傳出細(xì)胞作用、細(xì)胞因子產(chǎn)生（IL-10、IFN-γ和TNF-α）和趨化性。

艾美捷InVivoMAb抗人VISTA：

貨號(hào) BXC-BE0436

同型：小鼠IgG1，κ鏈

推薦同型對(duì)照：InVivoMAb小鼠IgG1同型對(duì)照，未知特異性

推薦稀釋液：InVivoPure pH 7.0稀釋液

免疫原：不可用或未知

報(bào)告應(yīng)用：石蠟切片免疫組化

流式細(xì)胞術(shù)

配方：PBS，pH 7.0

不含穩(wěn)定劑或防腐劑

內(nèi)毒素：<2EU/mg（<0.002EU/μg）

由LAL凝膠凝固法測(cè)定

純度：>95%

由SDS-PAGE測(cè)定

無(wú)菌性：0.2微米過濾

生產(chǎn)：在無(wú)動(dòng)物設(shè)施中從細(xì)胞培養(yǎng)上清液中純化

純化：蛋白G

分子量：150 kDa

儲(chǔ)存：抗體溶液應(yīng)以原液濃度在4°C下儲(chǔ)存。不要冷凍。

InVivoMAb抗人VISTA文獻(xiàn)參考：

Flow Cytometry

Deng J, Li J, Sarde A, Lines JL, Lee YC, Qian DC, Pechenick DA, Manivanh R, Le Mercier I, Lowrey CH, Varn FS, Cheng C, Leib DA, Noelle RJ, Mabaera R. (2019). "Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment" Cancer Immunol Res 10.1158/2326-6066.CIR-18-0507.

Immunohistochemistry (paraffin)

Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS. (2018). "VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival" Cancer Immunol Immunother 10.1007/s00262-018-2169-1.

Flow Cytometry

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P. (2018). "Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma" Target Oncol 10.1007/s11523-018-0595-9.

Immunohistochemistry (paraffin)

Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. (2014). "VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy" Cancer Immunol Res 10.1158/2326-6066.CIR-14-0072.